In a Phase 1 Trial, UB-312 Lowers α-Synuclein in Parkinson's Disease.

Published Date: 21 Mar 2024

Research presented at AD/PD 2024 revealed that UB-312 antibodies lower α-synuclein levels in Parkinson disease patients' cerebrospinal fluid, according to new results from a phase 1 trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

2.

New drug combination shows good results in patients with HPV-negative head and neck cancer

3.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

4.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

5.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot